Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moleculon

Executive Summary

Becomes subsidiary of Australian international health care company F. H. Faulding with Faulding's purchase of a further 19% of Moleculon stock in accordance with a put/call agreement reached in December 1988. Purchase, for $ 2.2 mil., gives Faulding control of approximately 52% of Moleculon and represents the remaining holdings of company founder Arthur Obermayer and his affiliates. Faulding also holds a $ 24.5 mil. stake in 8.5% convertible preferred units which, if converted to common stock, would give them 70% control. Faulding says it plans to expand the Kalipharma generics business, acquired by Moleculon in October 1989.
UsernamePublicRestriction

Register

PS018011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel